Sullivan & Cromwell LLP Logo
  • Home
  • Lawyers
  • Practices
  • Insights
  • About
  • Careers
  • Alumni
  • Twitter icon
  • LinkedIn icon
  •  icon
  • Podcasts icon
© 2025 Sullivan & Cromwell LLP
    • Home
    • Lawyers
    • Practices
    • Insights
    • About
    • Careers
    • Alumni
    Home /  Lawyers /  RuiHui (Rachel) Yu

    RuiHui (Rachel) Yu

    Partner

    RuiHui (Rachel) Yu Headshot Photo Portrait backdrop

    New York

    +1-212-558-4000

    |

    yuru@sullcrom.com

    Email vCard

    RuiHui (Rachel) Yu is a partner in Sullivan & Cromwell’s General Practice Group. Ms. Yu’s practice concentrates on transactional work involving complex technology, intellectual property, and cybersecurity issues, including mergers and acquisitions, divestitures, licenses and transfers of intellectual property, joint ventures, research and development agreements, collaborations, data agreements, financings, settlements and strategic advice. She counsels clients in a wide range of industries, including healthcare and life sciences, software and other technology, consumer and retail, financial services, and media and telecommunications. Ms. Yu was named one of the world’s leading patent professionals by IAM Patent 1000 (2024, 2025), named by MergerLinks as a “Top Intellectual Property Lawyer” for North America (2023) and named by The Best Lawyers in America: Ones to Watch for Intellectual Property Law (2022).

    A thought-leader in the field, Ms. Yu is a Lecturer in Law at Columbia Law School, where she teaches a course on IP transactions. She also regularly speaks on topics involving intellectual property and trademark law and artificial intelligence.

    Ms. Yu is also committed to pro bono. For many years, she has co-led the Legal Aid Society’s Associates’ Campaign in its annual fundraising efforts at the firm. Most recently, she has also represented clients in transgender name changes, in an uncontested divorce case and through the Clemency Project.

    Read More

    Spotlight

    Rachel Yu Named to IAM Patent 1000

    Read More
    awards_483-x-180_gold2

    S&C Advises B-Flexion in Boston Pharmaceuticals’ $2 Billion Sale to GSK

    Read More

    S&C Advises Codelco in Deal with Rio Tinto to Develop Lithium Project in Chile

    Read More

    Rachel Yu, Bradley King and Jack Baum Author Law360 Article on GenAI Compliance in Life Sciences

    Read More

    S&C Advises SmartBiz in Receiving Regulatory Approval To Acquire a Bank

    Read More
    • Experience
    • News
    • Publications, Videos and Podcasts
    • Credentials
    • Related Practices
    Experience

    Experience

    Healthcare & Life Sciences

    • Abiomed in its $18 billion acquisition by Johnson & Johnson, the largest all-cash change of control in the medtech space
    • A consortium led by Ally Bridge Group Capital Partners, in its acquisition of WuXi PharmaTech for approximately $3.3 billion – one of the largest going-private transactions, as well as one of the largest leveraged buyouts for a Chinese business
    • Amgen in its $27.8 billion acquisition of Horizon Therapeutics and approximately $1.9 billion acquisition of Five Prime Therapeutics
    • Anika Therapeutics in its acquisitions of Arthrosurface for up to $100 million and Parcus Medical for up to $95 million

    • Aurobindo Pharma USA in its collaboration and license agreement with a global pharma major
    • Bausch Health (formerly Valeant Pharmaceuticals) in its collaboration agreement with AstraZeneca, under which Valeant was granted an exclusive license to develop and commercialize brodalumab, acquisition of Commonwealth Laboratories’ business in the United States and Canada and acquisition of Unilens Vision for approximately $28 million
    • Bayer AG in its $66 billion acquisition of Monsanto Company and approximately $9 billion divestiture in assets to BASF, and the $7.6 billion sale of its animal health business to Elanco Animal Health
    • Biohaven Pharmaceuticals in Pfizer’s $11.6 billion acquisition of all outstanding shares of Biohaven not already owned by Pfizer, acquisition of Channel Biosciences, a subsidiary of Knopp Biosciences, and its Kv7 channel targeting platform, $1.24 billion strategic commercialization arrangement with Pfizer for rimegepant, commercialized as Nurtec® ODT in the U.S., in markets outside of the United States upon approval, and sale of tiered, sales-based participation rights on future global net sales of products containing rimegepant (BHV-3000) or BHV-3500 and certain derivative compounds thereof to Royalty Pharma for $100 million
    • Novartis in its $9.7 billion acquisition of The Medicines Company
    • Oaktree Capital Management in its debt capitalization transaction with Oxford Biomedica
    • Royal Phillips in its acquisition of the Healthcare Information Systems business of Carestream Health and $2 billion acquisition of The Spectranetics Corporation
    • Seagen in its $43 billion acquisition by Pfizer
    • Stemcentrx in its $9.8 billion acquisition by AbbVie
    • Sumitovant Biopharma and Sumitomo Pharma in their $2.9 billion acquisition of Myovant Sciences
    • Sumitovant Biopharma in the collaboration of its subsidiary Myovant Sciences with Pfizer to develop and commercialize Sumitovant’s ORGOVYXTM (relugolix)
    • Terumo Corporation in its $1.12 billion acquisition of certain products from Abbott Laboratories and St. Jude Medical
    • UnitedHealth Group in its divestiture of ClaimsXten, the claims editing business of Change Healthcare, to an affiliate of investment funds of TPG Capital for $2.2 billion
    • Verily Life Sciences, an Alphabet company, in connection with Temasek’s $800 million investment in Verily in exchange for a minority stake in the company

    Technology

    • Ally Financial in its $2.65 billion proposed acquisition of CardWorks, later terminated
    • AST SpaceMobile in its common stock purchase agreement with B. Riley Principal Capital, pursuant to which AST SpaceMobile sold and issued up to $75 million of its Class A Common Stock to B. Riley
    • Fifteen major universities in a joint patent licensing program called University Technology Licensing Program
    • Harris Corporation in its $35 billion merger of equals with L3 Technologies and its $350 million sale of its Night Vision business to Elbit Systems of America
    • The underwriters of Mobileye Global Inc. in its $861 million SEC-registered IPO and Nasdaq Global Select Market listing
    • Oaktree Capital Management in connection with its strategic investment in Acumera
    • Rio Development in connection with its team joining Eigen Labs and acquisition of the code and intellectual property from Rio Network by the Eigen Foundation
    • Unisys Corp. in its $1.2 billion sale of its U.S. federal business to Science Applications International Corp.
    • Watlow Electric Manufacturing Company in its sale to Tinicum L.P.
    • Yuga Labs in its acquisition of PROOF
    • Ziff Davis in its asset purchase agreement for Gawker Media Group’s media properties Gizmodo, Lifehacker, Kotaku, Jalopnik, Deadspin, Jezebel and Gawker

    Retail and Consumer

    • Anheuser-Busch InBev in various strategic transactions, including the extension of its nearly 40-year partnership with FIFA as the official beer sponsor of the FIFA Women’s World Cup 2023™ and the FIFA World Cup 2026™, its Worldwide Olympic Partnership through 2028 with the International Olympic Committee, through which AB InBev’s Corona Cero will be the global beer sponsor of the Olympic Games, its strategic relationship with a consortium of investors led by Apollo Global Management, which acquired a $3 billion minority stake in AB InBev’s U.S.-based metal container plants, divestiture of Craft Brew Alliance’s Kona Brewing Operations in Hawaii to PV Brewing Partners, and its acquisition of ready-to-drink, cider and craft beer brands for the Canadian and other markets from the Mark Anthony Group of companies
    • Booking Holdings in its $1.2 billion acquisition of Getaroom from Court Square Capital Partners
    • Grupo Carrefour Brasil in its approximately $1.2 billion acquisition of Grupo BIG Brasil SA from Advent International and Walmart
    • Haleon Group in its demerger from the GSK Group, making Haleon the world’s biggest stand-alone consumer health company
    • Panera Bread Company in its $7.5 billion acquisition by JAB
    • Sotheby’s in its acquisition of Viyet, an online marketplace for interior design
    • TheNotCompany in its joint venture with The Kraft Heinz Company
    • Tiffany & Co. in its acquisition by LVMH Moët Hennessy for approximately $16 billion

    Other Representations

    • A sovereign wealth fund in its acquisition of a minority interest in Sotheby’s whereby Bidfair will also invest additional capital alongside the sovereign wealth fund and remain Sotheby’s majority owner, resulting in a total investment of approximately $1 billion
    • Bosch in its pending acquisition of the global HVAC solutions business for residential and light commercial buildings from Johnson Controls and the acquisition of the Johnson Controls-Hitachi Air Conditioning joint venture for approximately $8 billion
    • Christopher M. George in his pending acquisition of Greenwoods Financial Group and its wholly-owned subsidiary, Greenwoods State Bank
    • DS Smith in its $585 million sale of the Plastics division to Olympus Partners; and Insight Enterprises in its $581 million acquisition of PCM
    • Fletcher Building in its $840 million sale of the Formica Group to Broadview Holding
    • TS Innovation Acquisitions Corp., a SPAC formed by Tishman Speyer Properties, in its $1.56 billion merger with Latch and $190 million PIPE in connection with the merger
    Read More
    News

    News

    • S&C Advises B-Flexion in Boston Pharmaceuticals’ $2 Billion Sale to GSK

      May 30, 2025
    • S&C Advises Codelco in Deal with Rio Tinto to Develop Lithium Project in Chile

      May 27, 2025
    • S&C Advises SmartBiz in Receiving Regulatory Approval To Acquire a Bank

      March 19, 2025
    • S&C Advises AB InBev in Extending Worldwide Olympic Partnership Through 2032

      February 26, 2025
    • S&C Advises Jiangsu Hengrui Pharmaceuticals in Exclusive License Agreement with IDEAYA Biosciences

      January 7, 2025
    • S&C Advises AB InBev in FIFA Sponsorship Agreement

      December 6, 2024
    Read More
    Read More
    Publications, Videos and Podcasts

    Publications, Videos and Podcasts

    • Rachel Yu, Bradley King and Jack Baum Author Law360 Article on GenAI Compliance in Life Sciences

      Articles May 22, 2025
    • Rachel Yu, Jay Thornton and Patrick Ronan Author Article on IP Contracting Following FTC’s Non-Compete Ban for Bloomberg Law

      Articles June 21, 2024
    • Rachel Yu and KJ Lim Author Bloomberg Law Article on Intellectual Property Considerations for AI Art

      Articles March 20, 2023
    • Rachel Yu, Elizabeth Cheung, Elianne Neuman Schiff and Rita Carrier Co-Author Bloomberg Law Article on Trademark Considerations for Naming Joint Ventures

      Articles July 7, 2023
    • Rachel Yu, KJ Lim and Jisoo Park Co-Author Law360 Article on Virtual Goods Brand Protection in the Licensing Context

      Articles July 6, 2023
    Read More
    Credentials

    Credentials

    Education

    • Stanford Law School, J.D., 2014
    • Stanford University, M.S., 2014
    • Princeton University, A.B., 2011

    Bar Admissions

    • New York
    Read More
    Related Practices

    Related Practices

    • General Practice
    • Artificial Intelligence
    • Consumer & Retail
    • Cybersecurity
    • Digital Assets
    • Fintech
    • Healthcare & Life Sciences
    • Intellectual Property & Technology Transactions
    • Privacy
    • Technology
    • Trade Secrets
    Sullivan & Cromwell LLP Logo

    Sending an e-mail through this web site does not create an attorney-client relationship. You should not send us any information through this web site that you would want treated confidentially.

    Accept
    Sullivan & Cromwell LLP Logo
    • Twitter icon
    • LinkedIn icon
    • RSS Feed icon
    • Podcasts icon
    • Home
    • Contact Us
    • Information Policy Relating to Cookies
    • Privacy Policy
    • California Privacy Policy
    • Website Notice
    • Attorney Advertising Notice
    © 2025 Sullivan & Cromwell LLP